These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18311895)

  • 1. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
    Palanki MS; Akiyama H; Campochiaro P; Cao J; Chow CP; Dellamary L; Doukas J; Fine R; Gritzen C; Hood JD; Hu S; Kachi S; Kang X; Klebansky B; Kousba A; Lohse D; Mak CC; Martin M; McPherson A; Pathak VP; Renick J; Soll R; Umeda N; Yee S; Yokoi K; Zeng B; Zhu H; Noronha G
    J Med Chem; 2008 Mar; 51(6):1546-59. PubMed ID: 18311895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
    Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M
    Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.
    Doukas J; Mahesh S; Umeda N; Kachi S; Akiyama H; Yokoi K; Cao J; Chen Z; Dellamary L; Tam B; Racanelli-Layton A; Hood J; Martin M; Noronha G; Soll R; Campochiaro PA
    J Cell Physiol; 2008 Jul; 216(1):29-37. PubMed ID: 18330892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
    Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
    Noronha G; Barrett K; Boccia A; Brodhag T; Cao J; Chow CP; Dneprovskaia E; Doukas J; Fine R; Gong X; Gritzen C; Gu H; Hanna E; Hood JD; Hu S; Kang X; Key J; Klebansky B; Kousba A; Li G; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Shi F; Soll R; Splittgerber U; Stoughton S; Tang S; Yee S; Zeng B; Zhao N; Zhu H
    Bioorg Med Chem Lett; 2007 Feb; 17(3):602-8. PubMed ID: 17113292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.
    Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2620-6. PubMed ID: 18515591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
    Bhide RS; Cai ZW; Zhang YZ; Qian L; Wei D; Barbosa S; Lombardo LJ; Borzilleri RM; Zheng X; Wu LI; Barrish JC; Kim SH; Leavitt K; Mathur A; Leith L; Chao S; Wautlet B; Mortillo S; Jeyaseelan R; Kukral D; Hunt JT; Kamath A; Fura A; Vyas V; Marathe P; D'Arienzo C; Derbin G; Fargnoli J
    J Med Chem; 2006 Apr; 49(7):2143-6. PubMed ID: 16570908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
    Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
    J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related macular degeneration.
    Brucker AJ
    Retina; 2009 Jun; 29(6 Suppl):S2-4. PubMed ID: 19553791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia.
    Liang S; Pong K; Gonzales C; Chen Y; Ling HP; Mark RJ; Boschelli F; Boschelli DH; Ye F; Barrios Sosa AC; Mansour TS; Frost P; Wood A; Pangalos MN; Zaleska MM
    J Pharmacol Exp Ther; 2009 Dec; 331(3):827-35. PubMed ID: 19741150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
    Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.
    Grisanti S; Tatar O
    Prog Retin Eye Res; 2008 Jul; 27(4):372-90. PubMed ID: 18621565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting intraocular neovascularization and edema--one drop at a time.
    Aiello LP
    N Engl J Med; 2008 Aug; 359(9):967-9. PubMed ID: 18753655
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
    Tuñón J; Ruiz-Moreno JM; Martín-Ventura JL; Blanco-Colio LM; Lorenzo O; Egido J
    Surv Ophthalmol; 2009; 54(3):339-48. PubMed ID: 19422962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for age-related macular degeneration.
    Patel S
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.